AIFA Agenzia Italiana del Farmaco
Closure of Managed Entry Agreements (MEA) Yescarta Register
Users of the monitored Drug Registries are informed that, following the publication in the OJ of Determination No. 878/2022, starting from , the conditional payment methods are no longer applicable for the YESCARTA register for the following therapeutic indication:
Treatment of adult patients with refractory or relapsing primary mediastinal large B-cell lymphoma (PMBCL) after two or more lines of systemic therapy.
As reported in the press release published on 12.11.2019, for the register in question, no reimbursements managed by the AIFA platform were envisaged, but payments made by the extra-system hospital structure according to the outcomes monitored by the register.In this regard, please note that it is mandatory, also for the finalization of the negotiation agreement valid for patients already in treatment before , to fill in the re-evaluations scheduled on a periodic basis, as indicated in the form.
In order to summarize the situation regarding the currently active procedures, please refer to the table «Current status of reimbursement procedures», accessible from the related links box.
Monitoring Registers Office
Published on:
— Reproduction reserved and for personal use
— Download the complete document in PDF format from the link at the bottom of the page
Access to the site is limited and reserved for healthcare professionals
You have reached the maximum number of visits
Source — https://www.univadis.it/viewarticle/chiusura-managed-entry-agreements-mea-registro-yescarta